Archive by category | Regional Initiatives

CEITEC grows in Brno

CEITEC grows in Brno

The Central European Institute of Technology (CEITEC) is establishing an R&D infrastructure project that eventually will cost $300 million in Brno within the next three years. The money for the European centre of scientific excellence comes from the Operational Programme Research and Development for innovation of the European Structural funds. The institute, which will interconnect life sciences and technical fields, will be used by up to 600 scientists and by over 1,200 students, and also by Czech and foreign companies. It will also help the existing basic and applied research in the entire Czech Republic to achieve top levels.  Read more

Blue Sky funding

Blue Sky funding

I read “an article in The Scientist “:http://the-scientist.com/2011/10/17/nih-grants-funding-drops/ on funding with a little cynical laugh the other day. It described how “The success rate of the government agency’s grant applications has hit an all-time low” – of 17.4% of all applications. That’s just under one in five: consider, then, that a recent call by South Africa’s National Research Foundation for 40 prestigious Research Chairs in local universities was over-subscribed by at least 10 to 1 – and that was with pre-screening by the institutions. Another call for “blue sky” projects for rated researchers – open to all 2,300-odd such people – was for a total of R15 million a year, and was expected to cater for about 30 projects.  Read more

Registering a company in Malaysia

Registering a company in Malaysia

My last post discussed the biotech landscape in Malaysia. Now I want to talk about setting up a company there. Malaysians can register sole proprietorship firms and co-operatives, partnership firms, private limited and public limited companies with the Companies Commission of Malaysia (CCM). However, foreigners cannot set up sole proprietorship or partnerships in Malaysia, unless they have permanent residency (PR) or have availed citizenship under the “Malaysia My Second Home” (MM2H) program.  Read more

Biotech in Malaysia

Biotech in Malaysia

Malaysia is located in Southeast Asia with two distinct regions, namely Peninsular west Malaysia and East Malaysia. It has a population of approximately 28 million, and is famous for elegant and gigantic “PETRONAS Twin Towers” located in the heart of Kuala Lumpur (pictured above, at night).  Read more

Brazilian Biotech Map

Brazilian Biotech Map

The Br-Biotec, with the support of APEX-Brazil and the collaboration of BIORIO and CEBRAP, performed a significant evaluation of the biotechnology enterprises in Brazil. Partly the idea was to focus on identifying companies in Brazil that have biotech as their main activity or are developing major biotech projects.  Read more

India’s Vision 2020 – BioPharma Strategy – R&D

India’s Vision 2020 – BioPharma Strategy – R&D

In order for India’s biopharmaceutical players to compete effectively on the global scale for biosimilars market by 2020, the private sector as well as Government of India (GOI) will have to invest a considerable amount of capital in building the manufacturing capacity and skills base to provide the necessary enabling environment. The Department of Pharmaceuticals, GOI in partnership with Association of Biotechnology Led Enterprises (ABLE) and PricewaterhouseCoopers (PwC) have attempted to address this opportunity and provided the key recommendations into six broad sections, which you can read about here.  Read more

Czech Republic´s International Cooperation

Czech Republic´s International Cooperation

Few in the healthcare industry have not heard about Gilead Sciences’ success against HIV/AIDS and hepatitis B. Viread and Hepsera, the two flagship drugs for treating these conditions, were first conceived by Czech scientists in the Prague-based Institute of Organic Chemistry and Biochemistry, led by professor Antonin Holy. They discovered tenofovir disoproxil fumarate, the active ingredient in Viread, which is used to treat HIV/AIDS. Likewise, the hepatitis B drug Hepsera produced by Gilead Sciences is based on a compound discovered in Prof. Holy’s laboratory in Prague. As a result of previous cooperation between the institute and Gilead, Holy signed a contract with Gilead, offering his discoveries in basic research. Gilead took his work and further developed it.  Read more